Open Access Green as soon as Postprint is submitted to ZB.
CD27 is required for protective lytic EBV antigen specific CD8+ T cell expansion.
Blood 137, 3225-3236 (2021)
Primary immunodeficiencies in the co-stimulatory molecule CD27 and its ligand CD70 predispose for pathologies of uncontrolled Epstein Barr virus (EBV) infection in nearly all affected patients. We demonstrate that both depletion of CD27 positive cells and antibody blocking of CD27 interaction with CD70 causes uncontrolled EBV infection in mice with reconstituted human immune system components. While overall CD8+ T cell expansion and composition is unaltered after antibody blocking of CD27, only some EBV specific CD8+ T cell responses, exemplified by early lytic EBV antigen BMLF1 specific CD8+ T cells are inhibited in their proliferation and killing of EBV transformed B cells. This suggests that CD27 is not required for all CD8+ T cell expansions and cytotoxicity, but for a subset of CD8+ T cell responses that protect us from EBV infection.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
22.113
0.000
4
5
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Epstein-barr-virus; Linked Lymphoproliferative Disease; Natural-killer-cells; Combined Immunodeficiency; Cultured Lymphoblasts; Expression; Differentiation; Lymphoma; Humans; Family
Language
english
Publication Year
2021
HGF-reported in Year
2021
ISSN (print) / ISBN
0006-4971
e-ISSN
1528-0020
Journal
Blood
Quellenangaben
Volume: 137,
Issue: 23,
Pages: 3225-3236
Publisher
American Society of Hematology
Publishing Place
2021 L St Nw, Suite 900, Washington, Dc 20036 Usa
Reviewing status
Peer reviewed
Institute(s)
Research Unit Gene Vector (AGV)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-501500-001
WOS ID
WOS:000667997800007
PubMed ID
33827115
Erfassungsdatum
2021-05-28